Fundz

Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer

PRIVATEApr 28, 2026

Position

Chief Financial Officer

Company

Prilenia

Elisabeth Leiderman
BostonBiotechnologyHealth CareTherapeutics

Description

Prilenia Therapeutics has announced the appointment of Dr. Elisabeth Leiderman as Chief Financial Officer. Dr

Quick answer

Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer (April 28, 2026). Prilenia is based in Boston, Massachusetts, United States.

Who is the new Chief Financial Officer at Prilenia?
Prilenia named Elisabeth Leiderman Chief Financial Officer, announced April 28, 2026.
What did Prilenia announce on April 28, 2026?
Prilenia Therapeutics has announced the appointment of Dr. Elisabeth Leiderman as Chief Financial Officer.
What does Prilenia do?
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders.
Where is Prilenia based?
Prilenia is based in Boston, Massachusetts, United States.

Source: Fundz verified event record.

Who to call at Prilenia, and when

A new leader at Prilenia brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Prilenia raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Prilenia, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Prilenia. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Prilenia

Location

Boston, Massachusetts, United States

About

Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Prilenia changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Jina
Likely contact at this company
••••••••@••••••••

See Jina's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Prilenia's next move

Learn about Strategic plan

Prilenia changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.